Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of
Metastatic Colorectal Carcinoma: Results from Czech
Observational Registry

J 2015

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry

KOCÁKOVÁ, Ilona; Bohuslav MELICHAR; Ivo KOCÁK; Zbyněk BORTLÍČEK; Tomáš BÜCHLER et al.

Základní údaje

Originální název

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry

Autoři

Vydání

Anticancer Research, Athens, The International Institute of Anticancer Research, 2015, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.895

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00083299

Organizační jednotka

Lékařská fakulta

UT WoS

000355273800039

Klíčová slova anglicky

Bevacizumab; FOLFIRI; XELIRI; colorectal cancer

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 7. 2015 14:59, Soňa Böhmová

Anotace

V originále

Aim: To retrospectively compare the efficacy of two irinotecan-based chemotherapy regimens combined with bevacizumab in first-line therapy of metastatic colorectal cancer (mCRC). Patients and Methods: The data of 558 patients with mCRC treated with first-line bevacizumab plus irinotecan-containing regimen were obtained from the national CORECT registry that collects data of all patients with mCRC treated with targeted-agents. The treatment outcomes of patients treated with bevacizumab plus irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) were compared to patients treated with bevacizumab plus irinotecan and capecitabine (XELIRI). Results: Among 4,312 patients with CRC treated with bevacizumab, only 13% (558) received irinotecan-based chemotherapy. No significant differences were observed in terms of progression-free survival and overall survival between FOLFIRI and XELIRI groups. Moreover, the toxicity of both regimens was also comparable. Conclusion: This retrospective analysis confirms the comparable activity of FOLFIRI and XELIRI regimens when combined with bevacizumab.

Citovat

KOCÁKOVÁ, Ilona; Bohuslav MELICHAR; Ivo KOCÁK; Zbyněk BORTLÍČEK; Tomáš BÜCHLER; Ladislav DUŠEK; Luboš PETRUŽELKA; Milan KOHOUTEK; Jana PRAUSOVÁ; Jindřich FÍNEK; Beatrice MOHELNIKOVA-DUCHONOVA a Rostislav VYZULA. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry. Anticancer Research. Athens: The International Institute of Anticancer Research, 2015, roč. 35, č. 6, s. 3455-3461. ISSN 0250-7005.

@article{1305222,
   author = {Kocáková, Ilona and Melichar, Bohuslav and Kocák, Ivo and Bortlíček, Zbyněk and Büchler, Tomáš and Dušek, Ladislav and Petruželka, Luboš and Kohoutek, Milan and Prausová, Jana and Fínek, Jindřich and MohelnikovaandDuchonova, Beatrice and Vyzula, Rostislav},
   article_location = {Athens},
   article_number = {6},
   keywords = {Bevacizumab; FOLFIRI; XELIRI; colorectal cancer},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry},
   volume = {35},
   year = {2015}
}

TY  - JOUR
ID  - 1305222
AU  - Kocáková, Ilona - Melichar, Bohuslav - Kocák, Ivo - Bortlíček, Zbyněk - Büchler, Tomáš - Dušek, Ladislav - Petruželka, Luboš - Kohoutek, Milan - Prausová, Jana - Fínek, Jindřich - Mohelnikova-Duchonova, Beatrice - Vyzula, Rostislav
PY  - 2015
TI  - Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry
JF  - Anticancer Research
VL  - 35
IS  - 6
SP  - 3455-3461
EP  - 3455-3461
PB  - The International Institute of Anticancer Research
SN  - 02507005
KW  - Bevacizumab
KW  - FOLFIRI
KW  - XELIRI
KW  - colorectal cancer
N2  - Aim: To retrospectively compare the efficacy of two irinotecan-based chemotherapy regimens combined with bevacizumab in first-line therapy of metastatic colorectal cancer (mCRC). Patients and Methods: The data of 558 patients with mCRC treated with first-line bevacizumab plus irinotecan-containing regimen were obtained from the national CORECT registry that collects data of all patients with mCRC treated with targeted-agents. The treatment outcomes of patients treated with bevacizumab plus irinotecan, 5-fluorouracil and folinic acid (FOLFIRI) were compared to patients treated with bevacizumab plus irinotecan and capecitabine (XELIRI). Results: Among 4,312 patients with CRC treated with bevacizumab, only 13% (558) received irinotecan-based chemotherapy. No significant differences were observed in terms of progression-free survival and overall survival between FOLFIRI and XELIRI groups. Moreover, the toxicity of both regimens was also comparable. Conclusion: This retrospective analysis confirms the comparable activity of FOLFIRI and XELIRI regimens when combined with bevacizumab.
ER  -

KOCÁKOVÁ, Ilona; Bohuslav MELICHAR; Ivo KOCÁK; Zbyněk BORTLÍČEK; Tomáš BÜCHLER; Ladislav DUŠEK; Luboš PETRUŽELKA; Milan KOHOUTEK; Jana PRAUSOVÁ; Jindřich FÍNEK; Beatrice MOHELNIKOVA-DUCHONOVA a Rostislav VYZULA. Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry. \textit{Anticancer Research}. Athens: The International Institute of Anticancer Research, 2015, roč.~35, č.~6, s.~3455-3461. ISSN~0250-7005.

Přehled o publikaci